Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- US FDA Begins Review of Risks of Serious Bleeding in Patients Taking Dabigatran
December 9, 2011
- NHI Drug Pricing Subcommittee to Apply 80% Rule for Combination Drugs to Injectables, Topical Drugs
December 8, 2011
- Gov’t Tax Commission Decides to Extend Temporary R&D Tax Credits
December 8, 2011
- CSIMC Submits Opinion on Medical Fee Revision Including Views of Both Healthcare Providers and Medical Bill Payers
December 8, 2011
- MHLW Proposes Penalty for Companies that Receive Premium but Refuse Development Requests
December 8, 2011
- Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
- Representatives of Payers, Care Providers Argue Against Freeze on Prices of Essential Drugs
December 8, 2011
- 2010 Survey Shows OB/GYN Doctors, Surgeons Rise in Number
December 7, 2011
- MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”
December 6, 2011
- Orphan Drug Designation Approved for Everolimus, Tafamidis Meglumine
December 6, 2011
- Premium for New Drug Development to Be Continued on Trial Basis: CSIMC Expert Subcommittee
December 6, 2011
- 2010 Survey Shows Rise in Numbers of OB/GYN Doctors, Surgeons
December 6, 2011
- Takeda’s Novel ARB Azilva Recommended for Approval: PAFSC First Committee
December 5, 2011
- CSIMC General Assembly Points Out Some “Reckless” Evaluations on Policy Screening Report
December 5, 2011
- 80% Rule for Combination Drugs Will Be Applied to Injectables, Topical Drugs: MHLW Proposal
December 5, 2011
- MHLW Announces Results of Reexamination for Iressa, Remicade as Category I
December 5, 2011
- PAFSC 2nd Committee Recommends Designation of Thalidomide, Imatinib Mesylate as Orphan Drugs
December 5, 2011
- Decision on Price Freeze for Medically Essential Drugs to Be Postponed
December 5, 2011
- Expert Subcommittee Approves 60% Pricing Rule for Some New Generics Only
December 5, 2011
- NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…